Losing balance: Cytokine signaling and cell death in the context of hepatocyte injury and hepatic failure

European Cytokine Network

Volumn 13, Issue 4, 2002, Pages 377-383

  Luedde, Tom ^a   Liedtke, Christian ^a   Manns, Michael P ^a   Trautwein, Christian ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Apoptosis; Fas; Interleukin 6; Liver failure; NF KB; Tumor necrosis factor

Indexed keywords

CYTOCHROME C; CYTOKINE; FAS LIGAND; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CELL DEATH; CELL PROTECTION; IMMUNOREGULATION; LIVER CELL DAMAGE; LIVER FAILURE; MITOCHONDRION; MORBIDITY; MORTALITY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CYTOCHROME C GROUP; CYTOKINES; FAS LIGAND PROTEIN; HEPATOCYTES; HUMANS; INTERLEUKIN-6; LIVER FAILURE; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; MODELS, BIOLOGICAL; NECROSIS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036825005     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. O'Grady JG, Schalm SW, Williams R. 1993. Acute liver failure: redefining the syndromes. Lancet 342: 273.
2. Jalan R, Williams R. 2002. Acute-on-chronic Liver Failure: Pathophysiological Basis of Therapeutic Options. Blood Purif. 20: 252.
3. Rahman T, Hodgson H. 2001. Clinical Management of acute hepatic failure (Review). Intensive Care Med. 27: 467.
4. Lemasters JJ. 1999. Mechanisms of Hepatic Toxicity V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis (Review). Am. J. Physiol. 276: G1.
5. Kerr JF, Wyllie AH, Currie AR. 1972. Apoptosis, a basic biological phenomenon with wide-ranging implications in tissue kinetics (Review). Br. J. Cancer 26: 239.
6. Majno G, Joris I. 1995. Apoptosis, oncosis, and necrosis. An overview of cell death (Review). Am. J. Pathol. 146: 3.
7. Salvesen GS, Dixit VM. 1997. Caspases: intracellular signaling by proteolysis (Review). Cell 91: 443.
8. Neuman MG. 2001. Apoptosis in diseases of the liver (Review). Crit. Rev. Clin. Lab. Sci. 38: 109.
9. Grasl-Kraupp B, Ruttkay-Nedecky H, Koudelka H, Bukowska K, Bursch W, Schulte-Herrmann R. 1995. In situ detection of fragmented DNA (TUNEL-assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 21: 1465.
10. Qian T, Herman B, Lemasters JJ. 1999. The mitochondrial permeability transition mediates both necrotic and apoptotic death of hepatocytes exposed to Br-A23187. Toxicol. Appl. Pharmacol. 154: 117.
11. Faouzi S, Burckhardt BE, Hanson JC, Campe CB, Schrum LW, Rippe RA, Maher JJ. 2001. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kB-independent, caspase-3-dependent pathway. J. Biol. Chem. 276: 49077.
12. Schulze-Osthoff K, Ferrari D, Los M, Weisselborg S, Peter ME. 1998. Apoptosis signaling by death receptors (Review). Eur. J. Biochem. 254: 439.
13. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301.
14. Krammer PH. 1999. CD95 (APO-1/Fas)-mediated apoptosis: live and let die (Review). Adv. Immunol. 71: 163.
15. Galle PR, Krammer PH. 1998. CD95-induced apoptosis in human liver disease (Review). Semin. Liver. Dis. 18: 141.
16. Hug H, Strand S, Grambihler A, Galle J, Hack V, Stremmel W, Krammer PH, Galle PR. 1997. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J. Biol. Chem. 272: 28191.
17. Strand S, Hofmann WJ, Grambihler A, Hug H, Volkmann M, Otto G, Wesch H, Mariani SM, Hack V, Stremmel W. Krammer PH, Galle PR. 1998. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat. Med. 4: 588.
18. Tio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, Kanto T, Sasaki Y, Kasahara A, Hori M. 1998. Serum levels of suluble Fas antigen in chronic hepatitis C patients. J. Hepatol. 29: 517.
19. Tannapfel A, Kohlhaw K, Ebelt J, Hauss J, Liebert U, Berr F, Wittekind C. 1999. Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens. Transplantation 67: 1079.
20. Ryo K, Kamagowa Y, Ikeda I, Yamauchi K, Yonehara S, Nagata S, Hayashi N. 2000. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am. J. Gastroenterol. 95: 2047.
21. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzuwa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. 1993. Lethal effect of the anti-Fas antibody in mice. Nature 364: 806.
22. Bajt ML, Lawson JA, Vonderfecht SL, Gujral JS, Jaeschke H. 2000. Protection against Fas receptor-mediated apoptosis in hepatocytes and nonparenchymal cells by a caspase-8 inhibitor in vivo: evidence for a postmitochondrial processing of caspase-8. Toxicol. Sci. 58: 109.
23. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA. 72: 3666.
24. Kimura K, Taguchi T, Urushizaki I, Ohno R, Abe O, Furue H, Hattori T, Ichihashi H, Inoguchi K, Majima H, et al. 1987. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol. 20: 223.
25. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. 1988. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J. Clin. Oncol. 6: 1328.
26. Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA Jr. 1990. Role of tumor necrosis factor-α in the pathophysiological alterations after ischemia/reperfusion injury in the rat. J. Clin. Investig. 85: 1936.
27. Felver ME, Mezey E, McGuire M, Mitchel MC, Herlong HF, Veech GA, Veech RL. 1990. Plasma tumor necrosis factor-α predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin. Exp. Res. 14: 255.
28. Gonzales-Amaro R, Garcia-Monzon C, Garcia-Buey L, Moreno-Otero R, Alonso JL, Yague E, Pivel JP, Lopez-Cabrera M, Fernandez-Ruiz E, Sanchez-Madrid F. 1994. Induction of tumor necrosis factor alpha by human hepatocytes in chronic viral hepatitis. J. Exp. Med. 179: 841
29. Leist M, Gantner F, Naumann H, Bluethmann H, Vogt K, Brigelius-Flohe R, Nicotera P, Volk HD, Wendel A. 1997. Tumor necrosis factor-induced apoptosis during poisoning of mice with hepatotoxins. Gastroenterology 112: 923.
30. Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. 1988. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 2: 72.
31. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. 1990. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann. Intern. Med. 112: 917.
32. Streetz K, Leifeld L, Grundmann D, Ramakers J, Eckert K, Spengler U, Brenner D, Manns M, Trautwein C. 2000. Tumor necrosis factor α in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 119: 446.
33. Pfeffer K, Matsuyama T, Kundig M, Wakeha A, Kishhara K, Shahinian A, Wiegmann PK, Ohashi PS, Kronke M, Mak TW. 1993. Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 73: 457.
34. Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G. 1995. Concavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 21: 190.
35. Martin SJ, Green DR. 1995. Protease activation during apoptosis: death by a thousand cuts ? (Review) Cell. 82: 349.
36. Wolf BB, Green DR. 1999. Suicidal tendencies: apoptotic cell death by caspase family proteinases (Review). J. Biol. Chem. 274: 20049.
37. Ashkenazi A, Dixit VM. 1998. Death receptors: signaling and modulation (Review). Science 281: 1305.
38. Hsu H, Xiong J, Goeddel DV. 1995. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell. 81: 495.
39. Shimizu S, Eguchi Y, Kamiike W, Waguri S, Uchiyama Y, Matsuda H, Tsujimoto Y. 1996. Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors. Oncogene 13: 21.
40. Kroemer G, Zamzami N, Susin SA. 1997. Mitochondrial control of apoptosis (Review). Immunol. Today 18: 44.
41. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. 1998. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94: 481.
42. Li H, Zhu H, Xu CJ, Yuan J. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94: 491.
43. Zoratti M, Szabo I. 1995. The mitochondrial permeability transition (Review). Biochim. Biophys. Acta 1241: 139.
44. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME. 1998. Two CD95 (APO-1/Fas) signaling pathways. EMBO. J. 17: 1675.
45. Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA, Lemasters JJ. 1998. The mitochondrial permeability transition is required for tumor necorsis factor alpha-mediated apoptosis and cytochrome c release. Mol. Cell. Biol. 18: 6353.
46. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ. 1999. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400: 886.
47. Hsu H, Shu HB, Pan MG, Goeddel DV. 1996. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 84: 299.
48. Karin M, Lin A. 2002. 2002. NF-κB at the crossroads of life and death (Review). Nat. Immunol. 3: 221.
49. Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, de la Pompa JL, Ferrik D, Hum B, Iscove N, Ohashi P, Rothe M, Goeddel DV, Mak TW. 1997. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7: 715.
50. Liu ZG, Hsu H, Goeddel DV, Karin M. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis, while NF-κB activation prevents cell death. Cell. 87: 565.
51. Leist M, Gantner F, Bohlinger I, Germann PG, Tiegs G, Wendel A. 1994. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J. Immunol. 153: 1778.
52. Duckett CS. 2002. Apoptosis and NF-kB: the FADD connection. J. Clin. Invest. 109: 579.
53. Bannermann DD, Tupper JC, Kelly JD, Winn RK, Harlan JM. 2002. The Fas-associated death domain protein suppresses activation of NF-kappa B by LPS and IL-1 beta. J. Clin. Invest. 109: 419.
54. Kuhnel F, Zender L, Paul Y, Tietze MK, Trautwein C, Manns M, Kubicka S. 2000. NF-κB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem. 275: 6421.
55. Lenczowski JM, Dominguez L, Eder AM, King LB, Zacharchuk CM, Ashwell JD. 1997. Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis. Mol. Cell. Biol. 17: 170.
56. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, Lin A. 2001. Inhibition of JNK activation through NF-κB target genes. Nature 414: 313.
57. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, Cong R, Franzoso G. 2001. Induction of gadd45β by NF-κB donwregulates pro-apoptotic JNK signalling. Nature 414: 308.
58. Liu H, Lo CR, Czaja MJ. 2002. NF-κB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology 35: 772.
59. Liedtke C, Plumpe J, Kubicka S, Bradham CA, Manns MP, Brenner DA, Trautwein C. 2002. Jun kinase modulates TNF-dependent apoptosis in liver cells. Hepatology 36: 315.
60. Streetz KL, Luedde T, Manns MP, Trautwein C. 2000. Interleukin-6 and liver regeneration (Review). Gut 47: 309.
61. Trautwein C, Boker K, Manns MP. 1994. Hepatocyte and immune system: acute phase reaction as a contribution to early defence mechanisms (Review). Gut 35: 1163.
62. Zhang D, Sun M, Samols D, Kushner I. 1996. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J. Biol. Chem. 271: 9503.
63. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105.
64. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML. 1999. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J. Biol. Chem. 274: 23013.
65. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. 1991. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 77: 2794
66. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M, Kinoshita M. 1998. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol. 31: 391.
67. Streetz KL, Wustefeld T, Graw A, Kamino K, Tronche F, Betz U, Mueller W, Manns M, Trautwein C. 2001. The role of gp130 during acute-phase-reaction and liver injury. Hepatology 34:424 Part 2 Suppl.S (abstract).
68. Bajt ML, Vonderfecht SL, Jaeschke H. 2001. Differential protection with inhibitors of caspase-8 and caspase-3 in murine models of tumor necrosis factor and Fas receptor-mediated hepatocellular apoptosis. Toxicol. Appl. Pharmacol. 175: 243.
69. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J, Rose-John S. 1997. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 15: 142.
70. Rakemann T, Niehof M, Kubicka S, Fischer M, Manns MP, Rose-John S, Trautwein C. 1999. The designer cytokine hyperinterleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. J. Biol. Chem. 274: 1257.